Tags : Purdue Pharma

Eisai Terminates its Worldwide Development & Commercialization Agreement with Purdue

Shots: Purdue to receive one-time payment from Eisai, while releasing itself from rights to develop & commercialize lemborexant. Eisai acquires WW development and commercialization rights for lemborexant, previously held by Purdue in the deal of Aug’15 The termination enables Purdue to focus on oncology, non-opioid pain & CNS programs. In Aug’15, Eisai granted WW development […]Read More

Purdue Pharma Signs an Agreement with Alivio Therapeutics for its

Shots: Alivio to receive $14.75M upfront, $260M milestones, license exercise payments and royalties on sales of product from Purdue. Purdue to get an option to add more compounds to the agreement based on Alivio’s inflammation-targeting technology, including an option for equity investment in Alivio The company received funding of $3.3M from the US DOD Technology/Therapeutic […]Read More

Purdue Pharma Signs Exclusive License Agreement with Klaria for its

Shots: Klaria to receive $55.2M as total deal value, including $5.2M as near-term milestones and royalties on sales from Purdue. Purdue to get exclusive license rights to develop & commercialize Klaria’s KL-01401 Klaria will take care the manufacture and supply of KL-01401 developed using its own drug delivery technology and has granted it patent rights […]Read More